trending Market Intelligence /marketintelligence/en/news-insights/trending/CRmfB1o-s_OGlojv0z2J4w2 content esgSubNav
In This List

SEC subpoenas Ocular Therapeutix for info on eye pain drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


SEC subpoenas Ocular Therapeutix for info on eye pain drug

The U.S. Securities and Exchange Commission subpoenaed Ocular Therapeutix Inc. for documents and information related to its eye pain medicine Dextenza.

The regulator is seeking the company's relevant communications with the U.S. Food and Drug Administration and investors under the non-public, fact-finding query. The SEC told the company that the inquiry should not be construed as an indication of any violation or a negative opinion of a person, security or entity.

Ocular Therapeutix intends to fully cooperate with the SEC in this regard and does not intend to comment further on this matter unless and until this matter is closed or further action is taken by the SEC.